

# Neurology Order Form

Fax Completed Form To:

Phone:



*Ivy Specialty Infusion*  
an amerita company

PATIENT INFORMATION			
Patient Name:		Date of Birth:	
Address:		City/State/Zip:	
Home Phone:		Cell Phone:	
Secondary Contact:		Work Phone:	
Patient Diagnosis & ICD-10:		Height:                      Weight:	
Allergies:		<input type="checkbox"/> Male <input type="checkbox"/> Female	
PROVIDER INFORMATION			
Physician Name:		Lic.#:	
Practice Name:		DEA #:	
Address:		NPI#:	
Office Contact:		City/State/Zip:	
Phone:		Fax:	
Supervisory Physician (if applicable):			
PLEASE ATTACH			
<input type="checkbox"/> Patient demographics & front/back copy of all insurance cards (prescription & medical) <input type="checkbox"/> Recent office visit notes, history & physical, lab & pertinent procedure results <input type="checkbox"/> Current medication list & list of prior medications tried and failed (with dates) <input type="checkbox"/> Line access documentation/verification if applicable <input type="checkbox"/> Quantitative serum Immunoglobulin lab results ( <i>Uplizna only</i> ) <input type="checkbox"/> TB lab results within last 12 months ( <i>Uplizna only</i> )		<input type="checkbox"/> Vaccine status (any vaccination) and documentation of any recent vaccinations <input type="checkbox"/> HBV lab results within last 12 months ( <i>Uplizna only</i> ) <input type="checkbox"/> Date of diagnosis, current FVC%, ALSFRS-R score, and JourneyMate form ( <i>Radicava only</i> ) <input type="checkbox"/> Anti-acetylcholine receptor (AChR) antibody positive results ( <i>Vyvgart</i> ) <input type="checkbox"/> Letter of medical necessity if drug dosing or indication is outside of FDA guidelines	
NURSING & LAB ORDERS			
<b>Nurse Orders:</b> Nurse to provide assessment, teaching, lab draws, medication administration and vascular access device insertion and/or management per physician orders. <b>Flush Orders:</b> <i>NaCl 0.9%</i> - 5-10mL flush pre and post infusion and as needed <i>Heparin</i> - <input type="checkbox"/> 10units/mL ---OR--- <input type="checkbox"/> 100units/mL - 3-5mL flush after post-infusion NS flush if indicated to maintain line <b>Lab Orders:</b>			
Lab Date & Frequency:			
PRESCRIPTION ORDERS			
<b>Anaphylaxis Kit:</b> <input type="checkbox"/> Epinephrine 0.3mg IM as needed <input type="checkbox"/> Solu-cortef 250mg-500mg IV as needed <input type="checkbox"/> Solu-Medrol 60mg - 125mg IV as needed (Check all that apply) <input type="checkbox"/> Diphenhydramine _____ mg IV as needed <input type="checkbox"/> NS Hydration 500 ml IV over 30 minutes as needed <input type="checkbox"/> Other			
<b>Pre-Medications:</b> <input type="checkbox"/> Acetaminophen _____ mg PO _____ minutes prior to infusion <input type="checkbox"/> Solu-Medrol _____ mg IV _____ minutes prior to infusion (Check all that apply) <input type="checkbox"/> Diphenhydramine _____ mg <input type="checkbox"/> PO ---OR--- <input type="checkbox"/> IV _____ minutes prior to infusion <input type="checkbox"/> Other			
<b>Supply Orders:</b> All supplies for vascular access line care, drug administration kit(s), pump, and IV pole will be provided as necessary			
PRODUCT	PRESCRIPTION INFORMATION		REFILLS
Is this a first dose? <input type="checkbox"/> Yes <input type="checkbox"/> No   If No, when was last dose given? _____                      When is patient due for next dose? _____			
<input type="checkbox"/> KINSULA	<input type="checkbox"/> <b>Induction:</b> 700mg IV infusion via <input type="checkbox"/> gravity ---OR--- <input type="checkbox"/> pump over 30 minutes every 4 weeks x 3 doses		NONE
	<input type="checkbox"/> <b>Maintenance:</b> 1400mg IV infusion via <input type="checkbox"/> gravity ---OR--- <input type="checkbox"/> pump over 30 minutes every 4 weeks		_____
	<input type="checkbox"/> If missed dose, administer the same dose as soon as possible and continue every 4 weeks		_____
<input type="checkbox"/> RADICAVA	<input type="checkbox"/> <b>Induction:</b> 60mg IV infusion via <input type="checkbox"/> gravity ---OR--- <input type="checkbox"/> pump over 1 hour daily for 14 days followed by 14 day drug-free period		NONE
	<input type="checkbox"/> <b>Maintenance:</b> 60mg IV infusion via <input type="checkbox"/> gravity ---OR--- <input type="checkbox"/> pump over 1 hour daily for 10 days out of 14 day period followed by 14 day drug-free periods		_____
<input type="checkbox"/> UPLIZNA	<input type="checkbox"/> <b>Induction:</b> 300mg IV infusion via <input type="checkbox"/> gravity ---OR--- <input type="checkbox"/> pump over approximately 90 minutes at 0 and 2 weeks and <i>CBC lab testing every _____ months</i>		NONE
	<input type="checkbox"/> <b>Maintenance:</b> ( <i>starting 6 months from first infusion</i> ) 300mg IV infusion via <input type="checkbox"/> gravity ---OR--- <input type="checkbox"/> pump over approximately 90 minutes every 6 months		_____
<input type="checkbox"/> VYEPTI	<input type="checkbox"/> 100mg IV infusion via <input type="checkbox"/> gravity ---OR--- <input type="checkbox"/> pump over approximately 30 minutes every 12 weeks		_____
	<input type="checkbox"/> 300mg IV infusion via <input type="checkbox"/> gravity ---OR--- <input type="checkbox"/> pump over approximately 30 minutes every 12 weeks		_____
<input type="checkbox"/> VYVGART	10mg/kg IV infusion via <input type="checkbox"/> gravity ---OR--- <input type="checkbox"/> pump over at least 1 hour once every week for 4 weeks <i>*Up to max of 1200mg for patient weight of 120kg+ (Total volume is 125ml in NS solution)</i> Administer additional treatment cycles <input type="checkbox"/> every 50 days ---OR--- <input type="checkbox"/> Prescriber to evaluate treatment cycle frequency after completion of initial treatment cycle According to the Package Insert: Administer subsequent treatment cycles based on clinical evaluation; the safety of initiating subsequent cycles sooner than 50 days from the start of the previous treatment cycle has not been established.		_____
	1,008mg/11,200 units subcutaneous injection over approximately 30 to 90 seconds in cycles of once weekly injections for 4 weeks Administer additional treatment cycles <input type="checkbox"/> every 50 days ---OR--- <input type="checkbox"/> Prescriber to evaluate treatment cycle frequency after completion of initial treatment cycle According to the Package Insert: Administer subsequent treatment cycles based on clinical evaluation; the safety of initiating subsequent cycles sooner than 50 days from the start of the previous treatment cycle has not been established.		_____
<input type="checkbox"/> IG	<b>Refer to Immunoglobulin Form</b>		_____
<input type="checkbox"/> SOLIRIS/ULTOMIRIS	<b>Refer to Soliris or Ultomiris Order Form</b>		_____
<input type="checkbox"/> OTHER			NONE
<b>By signing this form and utilizing our services, you are authorizing Amerita to assist with prior authorization requests acting as your pharmacy provider in dealing with medical and prescription insurance companies.</b>			

Prescriber's Signature	Print Name	Date	Prescriber's Signature	Print Name	Date
------------------------	------------	------	------------------------	------------	------



ACHC  
ACCREDITED

ACCREDITED  
Compounding Pharmacy